Tagged with S

Union of Professional Pharmaceutical Organizations (SPFO) Last time Focus Reports met with you in 2006, the Russian pharmaceutical industry had enjoyed five straight years of growth. This growth has since continued through 2011. Can you provide some insight on what has happened in the industry since 2006, and how the market has been able to maintain…

GlaxoSmithKline Pharmaceuticals Limited - Ind A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew Witty has publicly announced to pursue acquisitions here, growth has largely been organically. Is it too late for GSK to…

Sunil Parekh With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations from the Indian Institutes of Technology Graduates which you chair. In your view, what are Gujarat’s unique strengths? The one…

Russo-British Chamber of Commerce (RBCC) There is a long history of trade between Russia and Britain. The Chamber of Commerce started in 1916. Can you outline how the organisation has evolved and its current role today? As you point out, the Chamber was founded in 1916 – an interesting decision considering that we were in…

Malaysia External Trade Development Corporation (MATRADE) How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is in place? There are several key factors which make Malaysia a highly conducive environment for foreign companies to carry out…

Calyx Chemicals and Pharmaceuticals Limited You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the vision was to become a specialized API player, which could cater to both the Indian market and the international market.…

Glenmark Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it across 140 countries. What stage of the process are you in? When will we see India’s first novel drug in…

OctoPlus N.V. Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising. In your view, what makes OctoPlus stand out in the market? There are two main components, one being the people…

Pfizer Nehterlands Pfizer is well placed for the next generation of growth. Coming off great M&A’s and now restructuring internally, (from the country structure to the business units). After closing 2010, the first full year since changes have been incorporated, what have been the effects here for the Dutch affiliate? How has…

Utrecht Science Park (USP) Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths of the city of Utrecht? This science park has two focuses: life sciences and sustainability, which particularly focuses on climate…

CRC - Center for Clinical Research Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right time for a drive forward in clinical trials? Dr. Goh Pik Pin (GPP): Malaysia does offer a strong base for…

KPMG Netherlands While doing our research we couldn’t help but notice that you are quite passionate about issues related to healthcare and an avid proponent of healthcare reform. In this vein, what would be the ideal situation for the national healthcare system of the Netherlands and how should the country get there?…